NEWS: Prism now features protocol for Depression and tools for patient engagement.
Prism Suite.
Powered by the Brain.
Introducing Prism, an interventional psychiatry suite
of solutions powered by fMRI-informed digital biomarkers
for personalized patient care.
GrayMatters Health is leading a transformation bringing evidence-based, accessible technology to psychiatry to augment standard-of-care therapies and help improve patient outcomes and patient lives.
With a strong foundation in scientific research, Prism self-neuromodulation is being used in clinical practice to help patients get Back to Better. This innovation enables patients to learn to regulate brain activity associated with their mental health condition in the clinic, gaining a skill for use in their daily lives.
Prism is a comprehensive suite of solutions for scientifically leveraging the power of the brain, featuring two protocols and a toolbox to guide patient engagement:
-
PTSD. Patients learn to down-regulate an amygdala-based biomarker to treat symptoms associated with post-traumatic stress disorder (PTSD). Prism for PTSD is the first self-neuromodulation device to receive FDA clearance as a prescribed adjunct treatment for post-traumatic stress disorder (PTSD). Prism uses the amygdala-based biomarker to help patients regulate brain activity associated with PTSD symptoms. ​​​​
-
Depression. Patients learn to up-regulate the reward-system biomarker (Ventral Striatum based) to help live better with depression. ​​
​
[graph picture]
-
Insights. Data-based observations to help understand patient performance and progress and improve their overall Prism experience and providing possible conversation topics highlighting Prism best practices for better engagement.
Watch our Patient Animation:
Value for your patients and your practice
Leading-edge technology.
​
The ground-breaking fMRI-Informed digital biomarkers that power Prism have a strong scientific and clinical foundation. Since PTSD is associated with hyperactivity of the amygdala, the PTSD protocol uses an amygdala-based biomarker. On the other hand, anhedonic symptoms of Depression are associated with hypo activity of the reward system.
Operational Simplicity.​
​
Integrates seamlessly with clinic operational flow from intake to treatment. GMH provides onsite installation and training as well as in-person and remote support.
​
Personalized Care.​
​
In real-time, Prism reads the signal from the EEG sensors on the patient’s head and computes the relevant digital biomarker. These signals are the result of mental strategies the patient selects – this is as personal as a treatment can get.
​​​​​​​
​
Reduced Costs.​
​
Prism sessions can be administered by a technician to optimize clinician time and clinic resources.
